Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy As an Adjuvant Therapy for Pancreatic Cancer
Adjuvant Therapy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in Patients with Resected Pancreatic Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Zhong Wu, MD
- Phone Number: 028-85422851
- Email: wuzhong5555@126.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Recruiting
- West China Hospital, Sichuan University
-
Contact:
- Zhong Wu, MD
- Phone Number: 028-85422851
- Email: wuzhong5555@126.com
-
Contact:
- Zhong Wu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years and age ≤75 years.
- ECOG score 0-1.
- Patients with histologically confirmed pancreatic ductal adenocarcinoma, R0 resection, stage I-III, not receiving neoadjuvant therapy.
- Adequate bone marrow and organ function:
- Patients of childbearing potential must take appropriate precautions prior to enrollment and during the study.
- Signed informed consent.
- Ability to comply with the study protocol and follow-up.
Exclusion Criteria:
- Received antitumor chemotherapy, radiation therapy, or immunotherapy within 2 weeks prior to first vaccination.
- The patient has a history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or urothelial tumors (Ta and TIS), or other malignancies that have been treated with curative intent (at least 5 years prior to enrollment).
- Uncontrollable comorbidities, including but not limited to active bacterial or fungal infections, symptomatic congestive heart failure, unstable angina, arrhythmias.
- HIV infection or active hepatitis B (HBV DNA≥500IU/ml), hepatitis C.
- Uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease, or other conditions deemed ineligible by the investigator.
- Uncontrollable comorbidities, including but not limited to active bacterial or fungal infections, congestive heart failure, unstable angina, arrhythmias, etc;
- Patients with autoimmune diseases or immunodeficiencies being treated with immunosuppressive drugs.
- Pregnant or lactating women.
- Vaccination with other preventive vaccines within 4 weeks before the first administration or planned during the study period, including within 8 weeks after the last vaccination.
- Those who have had a severe allergic reaction to vaccines for other infectious diseases in the past.
- Those who may be allergic to the investigational product or any of its excipients.
- Substance abuse or inability to undergo immunotherapy due to clinical, psychological, or social factors.
- Significant weight loss (≥10%) within 6 weeks prior to enrollment.
- Any uncertain factors that may affect patient safety or compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
(1)8 cycles of Gemcitabine +capecitabine (Gemcitabine d1,8 ,Capecitabine d1-14 q3w);(2) two 200 mg intravenous dose of tislelizumab (d1,q3w)(3)five intravenous doses of neoantigen vaccines given as priming doses(d1,8,22,36,50)and two booster dose(d80,d110)
|
Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
18-month RFS
Time Frame: through study completion, an average of 2 year
|
defined recurrence as new lesions on the basis of response evaluation criteria in solid tumours (v.1.1),
and RFS from either the date of surgery (RFS) or from the date of the last neoantigen vaccine priming dose to the date of recurrence or death, whichever occurred first.
|
through study completion, an average of 2 year
|
|
Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
Time Frame: 3 months after the last administration of neoantigen vaccine
|
Defined by treatment-related adverse events as assessed by CTCAE v4.0
|
3 months after the last administration of neoantigen vaccine
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
18-month OS
Time Frame: through study completion, an average of 3 year
|
defined OS from the date of surgery to the date of death.
|
through study completion, an average of 3 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: zhong Wu, MD, West China Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHANT-231
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.